is tirzepatide a glp-1 agonist use tripled among non-diabetics, reaching $5.8B in 2022 Frontiers Comparing Ozempic, Wegovy and Other

These findings have generated considerable scientific interest

Research on GLP-1 medications for weight loss While more long-term studies are needed, the research on the effectiveness of GLP-1 medications for weight loss is promising

This personalized insight helps your provider set realistic expectations and optimize your treatment timeline

Rybelsus (semaglutide) is a GLP-1 receptor agonist that enhances insulin secretion and slows gastric emptying, whilst Jardiance (empagliflozin) is an SGLT2 inhibitor that increases urinary glucose excretion

Sermorelin is older, more widely available, often less expensive, and has a long history of use

Seven additional Phase 3 trial results are expected through 2026, with potential FDA submission in 2027